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Cefepime Neurotoxicity 
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Cefepime is a fourth-generation cephalosporin that is active against both gram-positive and gram-negative 
organisms. It is administered parenterally for the treatment of severe infections. Approximately 85% of the drug is 
excreted unchanged by the kidneys. Neurotoxicity in patients with renal failure who are treated with cefepime has 
been reported sporadically. We report on two senile patients with renal impairment who developed neurotoxicity 
including lethal outcome after treatment with cefepime.
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INTRODUCTION
  Cefepime, is a β-lactam antibiotic and a fourth-
generation cephalosporin that is highly eff  ective against 
both gram-positive and gram-negative bacteria. It is 
widely parenterally administered for severe infections.
1 
Eighty-fi  ve percent of the drug is excreted via the kidney, 
and adverse events in the central nervous system (CNS) 
related to encephalopathy have been sporadically 
reported in patients with decreased renal function.
2,3 
Recently, cases of neurotoxicity were reported in patients 
with normal renal function,
4 although the mechanism of 
the neurotoxicity was not established. Such cases of CNS 
toxicity are rare worldwide. We experienced two cases 
of neurotoxic adverse events related to cefepime that 
occurred in two elderly patients. Th   ese cases are reported 
here. 
CASE REPORTS
Case 1
  A 74-year-old male patient who had been undergoing 
hemodialysis for end-stage renal insufficiency for the 
previous 2 years underwent a laminectomy and L5 
irrigation at the Department of Orthopedics of Konkuk 
University Medical Center due to epidural abscess 
and septic spondylitis at L4-5. After the surgery, the 
patient experienced gait disturbance due to cauda 
equina syndrome and was transferred to the authors’ 
department for rehabilitation therapy. After surgical 
treatment for septic spondylitis, 1 g/day of cefepime 
was intravenously administered for 3 weeks. Blood 
chemistry fi  ndings such as acute infl  ammatory reaction 
levels stabilized, and the drug treatment was changed 
to a combination of amoxicillin and ciprofloxacin. The 
patient was on this combination drug for about 2 weeks. 
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Febrile findings emerged, however, and the patient’s 
blood chemistry revealed increases in erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) 
level, which refl  ect acute infl  ammatory levels, to 53 mm/
h (normal range 0-15 mm/h) and 6.27 mg/dl (normal 
range 0.01-0.3), respectively. Also, blood urea nitrogen 
(BUN) and creatinine, which reflect the level of renal 
function, had increased to 31.2 mg/dl (normal range 8.0-
22.0 mg/dl) and 5.2 mg/dl (normal range 0.7-1.4 mg/
dl), respectively. Th   e calculation using the modifi  ed diet 
for renal disease (MDRD) showed that the glomerular 
filtration rate (GFR) was 11 ml/min/1.73 m
2. Urinary 
tract infection was suspected. The drug treatment was 
changed again to intravenous administration of cefepime 
(1 g/day) for the treatment of urinary tract infection 
and previously identified lesions. On the third day of 
the cefepime administration, the patient complained 
of severe abdominal pain. Abdominal sonography 
and computed tomography (CT) were performed, but 
they revealed no particular findings. On the fourth 
day, the patient began falling into a state of stupor, 
was unable to recognize family members, groaned, 
constantly complained of abdominal pain, and refused 
meals and drug administration. On the fifth day of the 
administration, aphasia and complete disorientation 
occurred. Th   e patient’s biometric signs were stable, and 
blood chemistry was found to be similar to previous 
fi  nd  ings. On the sixth day of the administration, neuro-
toxicity due to cefepime was suspected and admini-
stration of antibiotics was stopped, and electro-
encephalography was performed. As epilepsy and a 
triphasic wave were observed, the administration of an 
anticonvulsant was initiated (Fig. 1). On the fifth day 
of the conservative treatment that was performed after 
the discontinuation of the administration of antibiotics, 
the patient’s consciousness and the findings from the 
electroencephalography improved. On the sixth day 
the electroencephalography findings were completely 
normal and the administration of the anticonvulsant 
was stopped. The patient recovered without particular 
sequelae.
Case 2
  A 77-year-old female patient had a cold for 2 weeks 
and could not eat nearly anything before presentation 
to the authors’ hospital. The patient had lost 20% body 
weight and systemic weakness was observed, and was 
hospitalized via the Department of Rehabilitation 
at Konkuk University Medical Center. The patient 
had a history of chronic renal dysfunction and was 
under a follow-up to determine the disease course. 
Blood chemistry analyses performed on the first day 
of hospitalization revealed an increased white blood 
cell (WBC) count (13.03×10³/μl; normal range 4-10/
μl) and urinalysis revealed pyuria. The patient also 
exhibited febricity. As urinary tract infection was 
suspected, ceftriaxone, as an empirical antibiotic, was 
intravenously administered (2 g/day). On the fi  rst day of 
hospitalization, the BUN and creatinine levels increased 
to 27.1 mg/dl (normal range 8.0-22.0 mg/dl) and 1.9 
mg/dl (normal range 0.7-1.4 mg/dl), respectively, 
and the calculations using MDRD showed that the 
GFR was 26 ml/min/1.73 m
2. After one week, the WBC 
level was 15.57×10³/μl. The results of the urinary tract 
test had not improved and urine culture for antibiotic 
susceptibility indicated the presence of bacteria resistant 
to ampicillin/clavulanic acid and cefoxitin/ciprofl  oxacin. 
Suspecting the elaboration of β-lactamase by the 
Fig. 1. EEG recordings in case 1 (A) and case 2 (B). The EEG recordings revealed diffuse slow-wave activity (delta) and 
triphasic sharp wave activity, suggesting a metabolic-toxic disturbance.Cefepime Neurotoxicity in Patients with Renal Insuﬃ   ciency
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resistant bacteria as the cause, the drug regimen was 
changed to intravenous administration of cefepime (1 
g/day). On the second day of cefepine use, the patient’s 
consciousness decreased with aphasia and a muscle 
clamp. Cefepime administration was stopped with 
follow-up. Brain CT showed no particular findings, and 
the electroencephalography revealed a triphasic wave 
(Fig. 1). Hemodialysis was performed. Three days later, 
the patient’s consciousness returned but the aphasia 
continued. Th   e patient subsequently experienced cycles 
of systemic improvement and aggravation. One month 
later, the patient died of a pneumonia complication.  
DISCUSSION
  Epilepsy related to β-lactam antibiotics can occur 
due to competitive antagonistic actions for gamma-
aminobutyric acid. This is attributed to the structural 
similarity between gamma-aminobutyric acid and a 
neurotransmitter.
5 Th   e mechanism remains unclear. Th  e 
mortality resulting from neurotoxicity related to cefepime 
has been reported to be higher than that from other 
β-lactam antibiotics.
6  
  Cefepime is excreted mostly via glomerular filtration, 
and its neurotoxicity has been reported mainly in patients 
with renal insufficiency.
2,3 Although cases of cefepine-
related neurotoxicity are sporadically reported, the drug’s 
empirical incidence rate has been reported as about 3%,
7 
although this fi  gure may be low.
8,9
  Previous studies reported that the time to the onset of 
symptoms (e.g., decrease in consciousness, epilepsy, 
aphasia, convulsion, and coma) from the administration 
of cefepime averages 5 days (range 1-10 days).
2,8 Th  e  two 
patients in this case report complained of neurological 
adverse events 2 and 4 days after the administration 
of cefepime, and their neurological symptoms 
included decrease in consciousness, disorientation, 
aphasia, convulsion, and anxiety. Both patients dis-
played a triphasic wave in electroencephalography, 
which suggested metabolic encephalopathy. The 
clear association with the antibiotic treatment from 
the viewpoint of the timing, and both clinical and 
electroencephalographic improvements after the 
discontinuation of the antibiotics (case 1), strongly 
suggest cefepime-related neurolotoxical adverse events.
  Diagnosis of such cases can be delayed by the presence 
of multiple factors, including old age, severe infection, 
multiple comorbidities, administration of multiple drugs, 
and the level of aggravation of medical diseases. Although 
the earliest discontinuation of the administration can 
be beneficial once a diagnosis was made,
8-10 one of our 
patients died. Many cases of adverse events related to 
safety and mortality have been reported,
2,3,6-8 and thus, 
care must be taken.
  In conclusion, we report on our experience with two 
cases of neurological adverse events caused by cefepime. 
More careful clinical consideration is required for 
patients who are elderly and have renal insuffi   ciency, and 
studies with various approaches to safety are required.
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